drugset / Trial / NCT05970627
Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
NaSingle-groupOpen-labelTreatment
Summary
This study is a prospective, single arm, multi-center phase II clinical trial designed to evaluate the efficacy and safety of perioperative SOX combined with toripalimab in participants with Epstein-Barr Virus-associated locally advanced gastric or esophagogastric junction adenocarcinoma.
Timeline
- Start
- 2023-07-28
- Primary completion
- 2026-07-28
- Completion
- 2029-07-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |
| Subject | S-1 | Small molecule | 80 mg | Oral |
| Subject | S-1 | Small molecule | 100 mg | Oral |
| Subject | S-1 | Small molecule | 120 mg | Oral |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |